Developed at the University of São Paulo, the model uses protein expression to create a stemness index that analyzes the similarity of tumors to pluripotent stem cells. The article was published in Cell Genomics.

BUFFALO, NY — July 15, 2025 — A new research paper was published in Aging (Aging-US) Volume 17, Issue 6, on June 5, 2025, titled “Senescence caused by telomerase inactivation in myeloid, mesenchymal, and endothelial cells has distinct effects on cancer progression.”

New research from Memorial Sloan Kettering Cancer Center (MSK) investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on the responsible governance of artificial intelligence in oncology; studies AI-assisted biomarker assessment in lung cancer; and demonstrates a cancer-trained large language model has strong predictive value.

Advances in blood stem cell transplants can now allow far more patients with blood cancers to receive lifesaving treatment, a study shows.

Researchers have developed a compact, affordable intraoral device that integrates diagnostic imaging and photodynamic therapy to detect and treat early-stage oral cancer. Designed for use in low-resource settings, the handheld tool uses fluorescence imaging to identify lesions and delivers targeted light therapy to destroy cancerous tissue. Preclinical studies in tissue models and mice demonstrated effective tumor reduction and capability for treatment monitoring. This innovation could significantly improve access to timely oral cancer care in regions with limited medical infrastructure.

Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yet many tumors remain resistant. Now, researchers at Korea University identifies the protein kinase WEE1 as a key driver of this resistance. They discovered that, outside its traditional role in the cell nucleus as tumor suppressor, cytoplasmic WEE1 fosters tumor growth and immune evasion by  enhancing AKT hyperactivation. Targeting WEE1 with clinically available inhibitors may re-sensitize tumors to immunotherapy, offering new hope for treatment-resistant cancer patients.